These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 30446460)

  • 21. An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies.
    Jager A; van Riel LAMJG; Postema AW; de Reijke TM; van der Sluis TM; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221111410. PubMed ID: 35924207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Power Doppler Sonography (PDS) and Modified TRUS Systematic Biopsies - Can this Combination Adequately Replace Multiparametric Prostate Magnetic Resonance Imaging (mp-MRI) in Candidates for Re Biopsies Who cannot Undergo mp-MRI.
    Kravchick S; Cherniavsky E; Peled R; Cytron S; Verhovsky G
    Pathol Oncol Res; 2020 Oct; 26(4):2357-2361. PubMed ID: 32504311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade.
    Scuderi S; Pellegrino F; Tin A; Beech BB; Gandaglia G; Stabile A; Eastham JA; Montorsi F; Briganti A; Vickers AJ
    Eur Urol Focus; 2024 May; 10(3):486-488. PubMed ID: 37739916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
    BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
    Jäderling F; Bergman M; Engel JC; Mortezavi A; Picker W; Haug ES; Eklund M; Nordström T
    BMC Urol; 2024 Aug; 24(1):168. PubMed ID: 39112967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
    Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
    World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    Chaloupka M; Pyrgidis N; Ebner B; Volz Y; Pfitzinger PL; Berg E; Enzinger B; Atzler M; Ivanova T; Clevert DA; Buchner A; Stief CG; Apfelbeck M
    BJU Int; 2024 May; 133(5):548-554. PubMed ID: 38060339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men.
    Kongnyuy M; Siddiqui MM; George AK; Muthigi A; Sidana A; Maruf M; Turkbey B; Choyke PL; Wood BJ; Pinto PA
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):348-351. PubMed ID: 28440325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
    Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
    Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
    Bittencourt LK; Guricova K; Zucker I; Durieux JC; Schoots IG
    Eur Radiol; 2022 Apr; 32(4):2330-2339. PubMed ID: 35028750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transperineal multiparametric magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy combined with standard template improves perineural invasion detection.
    Wu CL; Kim M; Wu S; Lin SX; Crotty RK; Harisinghani M; Feldman AS; Dahl DM
    Hum Pathol; 2021 Nov; 117():101-107. PubMed ID: 34461132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
    Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
    World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Porpiglia F; DE Luca S; Passera R; Manfredi M; Mele F; Bollito E; DE Pascale A; Cossu M; Aimar R; Veltri A
    Anticancer Res; 2016 Sep; 36(9):4833-9. PubMed ID: 27630337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.
    Okoro C; George AK; Siddiqui MM; Rais-Bahrami S; Walton-Diaz A; Shakir NA; Rothwax JT; Raskolnikov D; Stamatakis L; Su D; Turkbey B; Choyke PL; Merino MJ; Parnes HL; Wood BJ; Pinto PA
    J Endourol; 2015 Oct; 29(10):1115-21. PubMed ID: 25897467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
    Schoots IG; Roobol MJ; Nieboer D; Bangma CH; Steyerberg EW; Hunink MG
    Eur Urol; 2015 Sep; 68(3):438-50. PubMed ID: 25480312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
    Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
    Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions.
    Wang F; Chen T; Wang M; Chen H; Wang C; Liu P; Liu S; Luo J; Ma Q; Xu L
    BMC Urol; 2021 Dec; 21(1):183. PubMed ID: 34949183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.